SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 228 filers reported holding SAGE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,684 | -74.0% | 179 | -40.5% | 0.00% | – |
| Q2 2023 | $14,153 | -12.8% | 301 | -22.2% | 0.00% | – |
| Q1 2023 | $16,239 | +32.6% | 387 | +20.6% | 0.00% | – |
| Q4 2022 | $12,243 | -28.0% | 321 | -24.6% | 0.00% | -100.0% |
| Q3 2022 | $17,000 | +54.5% | 426 | +28.7% | 0.00% | – |
| Q2 2022 | $11,000 | +1000.0% | 331 | +2264.3% | 0.00% | – |
| Q4 2021 | $1,000 | 0.0% | 14 | -48.1% | 0.00% | – |
| Q3 2021 | $1,000 | -80.0% | 27 | -67.9% | 0.00% | – |
| Q2 2021 | $5,000 | -28.6% | 84 | -8.7% | 0.00% | – |
| Q1 2021 | $7,000 | -12.5% | 92 | 0.0% | 0.00% | – |
| Q4 2020 | $8,000 | -52.9% | 92 | -66.7% | 0.00% | -100.0% |
| Q3 2020 | $17,000 | +112.5% | 276 | +38.0% | 0.00% | – |
| Q2 2020 | $8,000 | +33.3% | 200 | 0.0% | 0.00% | -100.0% |
| Q1 2020 | $6,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |